Produced from sera of rabbits pre-immunized with highly pure (>98%) recombinant hPAI-1 (human Plasminogen Activator Inhibitor-1). Human PAI-1 specific antibody was purified by affinity chromatography employing immobilized hPAI-1 matrix.
SERPINE1
Reaktivität: Human
WB, IHC, ELISA, IF
Wirt: Kaninchen
Polyclonal
unconjugated
Applikationshinweise
Neutralization:
To yield one-half maximal inhibition [ND50] of the biological activity of hPAI-1 (4.5 μ,g/mL), a concentration of at least 15.0 μ,g/mL of this antibody is required.
ELISA: Indirect: To detect hPAI-1 by indirect ELISA (using 100 μ,L/well antibody solution) a concentration of 0.5 - 2.0 μ,g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with compatible secondary reagents, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hPAI-1.
Sandwich To detect hPAI-1 by sandwich ELISA (using 100 μ,L/well antibody solution) a concentration of 0.5 - 2.0 μ,g/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with our biotinylated Anti-Human PAI-1 as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant hPAI-1.
Western Blot: To detect hPAI-1 by Western Blot analysis this antibody can be used at a concentration of 0.1 - 0.2 μ,g/mL. Used in conjunction with compatible secondary reagents the detection limit for recombinant hPAI-1 is 1.5 - 3.0 ng/lane, under either reducing or non-reducing conditions.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Lagerung
-20 °C
Informationen zur Lagerung
PAI-1 antibody is stable for at least 2 years from date of receipt at -20°C. The reconstituted antibody is stable for at least two weeks at 2-8°C. Frozen aliquots are stable for at least 6 months when stored at -20°C. Avoid repeated freeze-thaw cycles.
PAI1 (plasminogen activator inhibitor 1) is originally cloned from human endothelial cell (Pannekoek 1986, Ginsburg 1986) and rat hepatoma cell 3 cDNA libraries. As a member of the serpin family of serine protease inhibitors, PAI1 inhibits both tissue type palsminogen activator (tPA) and urokinase type plasminogen activator (uPA). High PAI1 levels are associated with an increased risk of thromboembolic disease while PAI1 deficiency may represent an inherited autosomal recessive bleeding disorder.